**Supplementary Table 1.** SVR12 rates (95% CI) in patients infected with HCV GT3 and GT6 among different DAA regimens

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | All GT3SVR, % (95% CI) | GT3aSVR, % (95% CI) | GT3bSVR, % (95% CI) | GT6SVR, % (95% CI) |
| DAA regimens |  |  |  |  |
|  SOF/RBV(n = 82/22/30/22) | 91.5 (83.2-96.5) | 100 (84.6-100)\* | 100 (88.4-100)\* | 100 (84.6-100)\* |
|  SOF/DCV ± RBV(n = 102/25/35/16) | 88.2 (80.4-93.8) | 96.0 (79.6-99.9) | 88.6 (73.3-96.8) | 100 (79.4-100)\* |
|  GLE/PIB(n = 68/11/2/70) | 94.1 (85.6-98.4) | 100 (71.5-100)\* | 100 (15.8-100)\* | 100 (94.9-100)\* |
|  SOF/VEL ± RBV(n = 851/484/168/122) | 96.2 (94.7-97.4) | 98.1 (96.5-99.1) | 93.4 (88.6-96.7) | 97.5 (93.0-99.5) |
| SOF/LDV ± RBV(n = 24/6/6/219) | 95.8 (78.9-99.9) | 100 (54.1-100)\* | 100 (54.1-100)\* | 98.2 (95.4-99.5) |

\*one-sided, 97.5% confidence interval. HCV, Hepatitis C virus; SVR, Sustained virological response; GT, Genotype; DAA, Direct-acting antiviral; SOF, Sofosbuvir; VEL, Velpatasvir; RBV, Ribavirin; DCV, Daclatasvir; LDV, Ledipasvir; GLE, Glecaprevir; PIB, Pibrentasvir; CI, Confidence interval.